Electronic Resource
Intranasal sufentanil for cancer-associated breakthrough pain.
| العنوان: | Intranasal sufentanil for cancer-associated breakthrough pain. |
|---|---|
| المؤلفون: | Good P., Ashby M., Jackson K., Brumley D. |
| بيانات النشر: | SAGE Publications Ltd (55 City Road, London EC1Y 1SP, United Kingdom) United Kingdom 2012-10-13 |
| نوع الوثيقة: | Electronic Resource |
| مستخلص: | The objective of this study was to demonstrate the efficacy, safety and patient acceptability of the use of intranasal sufentanil for cancer-associated breakthrough pain. This was a prospective, open label, observational study of patients in three inpatient palliative care units in Australia. Patients on opioids with cancer-associated breakthrough pain and clinical evidence of opioid responsiveness to their breakthrough pain were given intranasal (IN) Sufentanil via a GO MedicalTM patient controlled IN analgesia device. The main outcome measures were pain scores, need to revert to previous breakthrough opioid after 30 min, number of patients who chose to continue using IN sufentanil, and adverse effects. There were 64 episodes of use of IN sufentanil for breakthrough pain in 30 patients. There was a significant reduction in pain scores at 15 (P < 0.0001) and 30 min (P < 0.0001). In only 4/64 (6%) episodes of breakthrough pain did the participants choose to revert to their prestudy breakthrough medication. Twenty-three patients (77%) rated IN sufentanil as better than their prestudy breakthrough medication. The incidence of adverse effects was low and most were mild. Our study showed that IN sufentanil can provide relatively rapid onset, intense but relatively short lasting analgesia and in the palliative care setting it is an effective, practical, and safe option for breakthrough pain. © 2009 SAGE Publications. |
| مصطلحات الفهرس: | open study, oxygen saturation, pain assessment, patient compliance, repeated drug dose, side effect/si [Side Effect], opiate/dt [Drug Therapy], sufentanil/ae [Adverse Drug Reaction], sufentanil/ct [Clinical Trial], sufentanil/do [Drug Dose], sufentanil/dt [Drug Therapy], sufentanil/na [Intranasal Drug Administration], human, drug delivery system, drug dose comparison, drug dose titration, drug efficacy, drug induced headache/si [Side Effect], drug safety, article, breathing rate, cancer pain/dt [Drug Therapy], cancer palliative therapy, clinical article, clinical trial, dose response, drowsiness/si [Side Effect], drug withdrawal, nausea/si [Side Effect], Article |
| URL: | Click here for full text options LibKey Link |
| الاتاحة: | Open access content. Open access content Copyright 2012 Elsevier B.V., All rights reserved. |
| Other Numbers: | AUSHL oai:repository.monashhealth.org:1/31267 Palliative Medicine. 23 (1) (pp 54-58), 2009. Date of Publication: 2009. 0269-2163 https://repository.monashhealth.org/monashhealthjspui/handle/1/31267 19144765 [http://www.ncbi.nlm.nih.gov/pubmed/?term=19144765] 354095058 (Good) Calvary Mater Newcastle, University of Newcastle, Callaghan, NSW, Australia (Jackson) Southern Health and Monash University, Monash Medical Centre, McCulloch House, Clayton, VIC, Australia (Brumley) Ballarat Health Services, Ballarat, VIC, Australia (Ashby) Royal Hobart Hospital, Department of Health and Human Services, Repatriation Centre, Hobart, TAS, Australia (Good) Calvary Mater Newcastle, Department of Palliative Care, Hunter Region Mail Centre, Locked Bag 7, Warabrook, NSW 2310, Australia Good P.; phillip.good@mater.health.nsw.gov.au 1305123801 |
| المصدر المساهم: | MONASH HEALTH LIBRS From OAIster®, provided by the OCLC Cooperative. |
| رقم الانضمام: | edsoai.on1305123801 |
| قاعدة البيانات: | OAIster |
| الوصف غير متاح. |